Charlotte Wessel Skovlund

Charlotte Wessel Skovlund

Auto-generated profile, based on publicly available information

Charlotte Wessel Skovlund

Cancer and Medicine, The Danish Cancer Institute, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2020 in Acta Oncologica
Verified
Journal Article
Closed access
CSCharlotte Wessel Skovlund
Charlotte Wessel Skovlund
SFSøren Friis
Søren Friis
CDChristian Dehlendorff
Christian Dehlendorff
MNMef Christina Nilbert
Mef Christina Nilbert
LMLina Steinrud Mørch
Lina Steinrud Mørch
Following the first case of acute respiratory syndrome coronavirus 2 (SARS-CoV-2, known as COVID-19) in Denmark at the end of February 2020, wide-spread social distancing was implemented and societ...

15 November 2023 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
PDF file
CSCharlotte Skriver
Charlotte Skriver
TMThomas Maltesen
Thomas Maltesen
CDChristian Dehlendorff
Christian Dehlendorff
CSCharlotte Wessel Skovlund
Charlotte Wessel Skovlund
MSMorten Schmidt
Morten Schmidt
SFSøren Friis
Søren Friis
Background: Long-term use of aspirin has been shown to reduce colorectal cancer risk, but the association remains inconclusive for individual noncolorectal cancers. We examined the association between long-term aspirin use and cancer risk in Denmark. Methods: Using nationwide registries, we followed individuals aged 40-70 years at baseline (January 1, 1997) for cancer diagnoses through 2018. We assessed low-dose (75-150 mg) aspirin use according to continuity, duration, and cumulative amount. In addition, we explored associations with consistent high-dose (500 mg) aspirin use. Using Cox regression, we estimated multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) with aspirin use for overall and site-specific cancer. Results: Among 1 909 531 individuals, 422 778 were diagnosed with cancer during mean follow-up of 18.2 years. Low-dose aspirin use did not reduce the hazard ratio for cancer overall irrespective of continuity and duration of use (continuous use: HR = 1.04, 95% CI = 1.03 to 1.06). However, long-term (≥5 or ≥10 years) use was associated with at least 10% reductions in hazard ratios for several cancer sites: colon, rectum, esophagus, stomach, liver, pancreas, small intestine, head and neck, brain tumors, meningioma, melanoma, thyroid, non-Hodgkin lymphoma, and leukemia. Substantially elevated hazard ratios were found for lung and bladder cancer. In secondary analyses, consistent high-dose aspirin use was associated with reduced hazard ratios for cancer overall (HR = 0.89, 95% CI = 0.85 to 0.93) and for several cancer sites. Conclusion: Long-term low-dose aspirin use was associated with slight to moderately reduced risks for several cancers but not for cancer overall owing to increased risk for some common cancers. Similar or slightly stronger inverse associations were observed for consistent use of high-dose aspirin.

12 January 2022 in Acta Oncologica
Verified
Journal Article
Open access
CSCharlotte Wessel Skovlund
Charlotte Wessel Skovlund
SFSøren Friis
Søren Friis
JCJane Christensen
Jane Christensen
MNMef Nilbert
Mef Nilbert
LMLina Steinrud Mørch
Lina Steinrud Mørch
Several countries have reported a decline in cancer diagnoses during the COVID-19 pandemic [1–7]. The European Cancer Organisation estimated that clinicians diagnosed 1.5 million fewer cancer patie...

16 September 2013 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Open access
PDF file
RVRie Adser Virkus
Rie Adser Virkus
ELEllen C.L. Løkkegaard
Ellen C.L. Løkkegaard
ØLØjvind Lidegaard
Øjvind Lidegaard
JLJens Langhoff‐Roos
Jens Langhoff‐Roos
LBLars Bjerregaard
Lars Bjerregaard
TBThomas Bergholt
Thomas Bergholt
Objective: The aim of this study was to describe venous thromboembolism (VTE) in pregnancy and the puerperal period, and to validate diagnoses of VTE.Design: Historical cohort study.Population: All pregnancies in Denmark from 1995 to 2009.Methods: VTE diagnoses were retrieved from national registries.Main outcome measures: Positive predictive value of a VTE diagnoses diagnosed during pregnancy or the puerperal period. Location of VTE. Incidence rate of confirmed, validated diagnoses of VTE and on all retrieved diagnoses of VTE.Results: In 1 297 037 pregnancies, 1436 women had a first‐ever VTE diagnosis. Hospital records were retrieved for 1210 women (84.3%). Almost all women had relevant clinical symptoms and in 796 (65.8%), the diagnosis were confirmed by a positive diagnostic test or by instituted anticoagulation treatment. In all, 72.6, 53.7, 58.5 and 79.1% of the diagnoses were confirmed in the first, second, third trimester and the puerperal period, respectively. The 796 cases of VTE included 624 women with deep venous thrombosis only and 133 with pulmonary embolisms. Deep venous thrombosis was located in the left lower limb in 83.8% in pregnancy, compared with 67.9% in the puerperal period.Conclusions: The vast majority of women with a registered diagnosis of VTE had relevant symptoms. Diagnoses of VTE were confirmed in the medical records in two of three women. VTE diagnoses were most often confirmed when made in the first trimester and in the puerperal period. Left‐sided deep venous thrombosis was the predominant type of VTE in pregnancy and the puerperal period.

5 January 2024 in The Lancet Regional Health - Europe
Verified
Journal Article
Open access
CSCharlotte Wessel Skovlund
Charlotte Wessel Skovlund
AMAmalie Lykkemark Møller
Amalie Lykkemark Møller
CTChristian Torp-Pedersen
Christian Torp-Pedersen
LMLina Steinrud Mørch
Lina Steinrud Mørch
AMAmani Meaidi
Amani Meaidi
Use of the high-dose levonorgestrel-releasing intrauterine system (LNG-IUS) has been associated with increased risk of incident depression. Evidence is lacking on the influence of use of two recently marketed low-dose LNG-IUS on risk of depression. This study aims to examine associations between use of different doses of LNG-IUS and risk of depression. We conducted a nationwide prospective cohort study involving all first-time users of an LNG-IUS among all Danish nulliparous women aged 15–34 years with no medical history of depression, major psychiatric diseases, endometriosis, heavy menstrual bleeding, polyp, myoma, dysmenorrhoea, iron supplement use, abortion, and infertility treatment. A total of 46,565 first-time users of LNG-IUS were followed for 80,516 person-years with 1,531 incident initiations of antidepressant use observed during follow-up. Use of the high-dose LNG-IUS containing 52 mg levonorgestrel was initiated by 9,902 (21%) women, while 20,665 (44%), and 15,998 (34%) initiated use of the low-dose LNG-IUS containing 19·5 mg and 13·5 mg levonorgestrel, respectively. The age-, calendar-time-, and education-standardised incidence rates of first-time depression per 1,000 person-years at full LNG-IUS duration were 30.8 (95% CI 23·6–39·5) for the 52 mg LNG-IUS, 19·8 (95% CI 16·1; 24·0) for the 19·5 mg LNG-IUS, and 17·7 (95% CI 14·4–21·5) for the 13·5 mg LNG-IUS-. Compared to the high-dose 52 mg LNG-IUS, the adjusted number of avoided depressions per 1,000 person-years were 11·0 (95% CI 7·1–14·9) for the 19·5 mg LNG-IUS and 13·1 (95% CI 9·6–16·6) for the 13·5 mg LNG-IUS. The corresponding adjusted rate ratios were 0·77 (95% CI 0·68; 0·88) and 0·85 (95% CI 0·75–0·96). The reduced risk of depression with low-dose LNG-IUS compared to high-dose LNG-IUS was observable throughout duration of use. Use of low-dose LNG-IUS containing 19·5 mg and 13·5 mg levonorgestrel, respectively, were associated with a reduced risk of incident depression compared to use of the high-dose 52 mg LNG-IUS. The study suggests that low-dose LNG-IUS should be preferred over the high-dose LNG-IUS for contraceptive purpose. Sygeforsikringen “Danmark” grant: 2021–0128.

13 June 2023 in Cancers
Verified
Journal Article
Open access
PDF file
LMLina Steinrud Mørch
Lina Steinrud Mørch
MGMads Gamborg
Mads Gamborg
CHCaroline Hallas Hemmingsen
Caroline Hallas Hemmingsen
CSCharlotte Wessel Skovlund
Charlotte Wessel Skovlund
SKSusanne K. Kjaer
Susanne K. Kjaer
MHMarie Hargreave
Marie Hargreave
Approximately 400 million women of reproductive age use hormonal contraceptives worldwide. Eventually, pregnancy sometimes occurs due to irregular use. Use in early pregnancy is found to be associated with child morbidities including cancer, the main reason for disease-related death in children. Here, we add the missing piece about in utero exposure to hormonal contraception and mortality in offspring, including assessments of prognosis in children with cancer. In utero exposure to hormonal contraception may be associated with death since we found a hazard ratio (HR) of 1.22 (95% confidence interval (CI) 1.01–1.48) compared to children of mothers with previous use. The HRs were 1.22 (95% CI 0.99–1.13) for oral combined products and 2.92 (95% CI 1.21–7.04) for non-oral progestin-only products. A poorer prognosis was also found in exposed children with leukemia (3.62 (95% CI: 1.33–9.87)). If causal, hormonal contraception in pregnancy seems detrimental for offspring health and a marker of poorer prognosis in children with leukemia.